References
- Alagkiozidis I, Facciabene A, Tsiatas M, et al (2011). Timedependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. J Transl Med, 25, 9-77.
- Amin MA, Mansfield PJ, Pakozdi A, et al (2007). IL-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum, 56, 1787-97. https://doi.org/10.1002/art.22705
- Asefi V, Mojtahedi Z, Khademi B, Naeimi S, Ghaderi A (2009). Hand neck squamous cell carcinoma is not associated with interleukin-18 promoter gene polymorphisms: a case-control study. J Laryngol Otol, 123, 444-8. https://doi.org/10.1017/S0022215108003733
- B Zhang, K-F Wu1, Y-M Lin, et al (2004). 1 Gene transfer of pro-IL-18 and IL-1b converting enzyme cDNA induces potent antitumor effects in L1210 cells. Leukemia, 18, 817-25. https://doi.org/10.1038/sj.leu.2403320
- Badiola I, Olaso E, Crende O, Friedman SL, Vidal-Vanaclocha F (2011). Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis. Gut.
- Bouzgarrou N, Hassen E, Schvoerer E, et al (2008). Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection. J Med Virol, 80, 607-14. https://doi.org/10.1002/jmv.21079
- Cao Q, Cai W, Niu G, He L, Chen X (2008). Multimodality imaging of IL-18--binding protein-Fc therapy of experimental lung metastasis. Clin Cancer Res, 14, 6137-45. https://doi.org/10.1158/1078-0432.CCR-08-0049
- Cao R, Farnebo J, Kurimoto M, Cao Y (1999). IL-18 acts as an angiogenesis and tumor suppressor. FASEB J, 13, 2195-202. https://doi.org/10.1096/fasebj.13.15.2195
- Carbone A, Vizio B, Novarino A, et al (2009). IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival. J Immunother, 32, 920-31. https://doi.org/10.1097/CJI.0b013e3181b29168
- Chattergoon MA, Levine JS, Latanich R, et al (2011). High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection. J Infect Dis, 204, 1730-40. https://doi.org/10.1093/infdis/jir642
- Cho D, Song H, Kim YM, et al (2000). Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res, 60, 2703-9.
- Cho ML, Jung YO, Moon YM, et al (2006). IL-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett, 103, 159-66. https://doi.org/10.1016/j.imlet.2005.10.020
- Coughlin CM, Salhany KE, Wysocka M, et al (1998). Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest, 101, 1441-52. https://doi.org/10.1172/JCI1555
- Cui G, Yuan A, Goll R, et al (2007). Distinct changes of dendritic cell number and IL-12 mRNA level in adjacent mucosa throughout the colorectal adenoma-carcinoma sequence. Cancer Immunol Immunother, 56, 1993-2001. https://doi.org/10.1007/s00262-007-0345-9
- Diakowska D, Markocka-Maczka K, Grabowski K, Lewandowski A (2006). Serum interleukin-12 and interleukin-18 levels in patients with oesophageal squamous cell carcinoma. Exp Oncol, 28, 319-22.
- Eissa SA, Zaki SA, El-Maghraby SM, Kadry DY (2005). Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. J Egypt Natl Canc Inst, 17, 51-5.
- Elaraj DM, Weinreich DM, Varghese S, et al (2006). The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res, 12, 1088-96. https://doi.org/10.1158/1078-0432.CCR-05-1603
- Elias AS, et al. 2009, PD-1 Induced IL10 Production by Monocytes Impairs T-cell Activation in a Reversible Fashion. Nature Medicine, 452-9.
- Farhat K, Hassen E, Bouzgarrou N, et al (2008). Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients. Cytokine, 43, 132-7. https://doi.org/10.1016/j.cyto.2008.05.004
- Farjadfar A, Mojtahedi Z, Ghayumi MA, et al (2009). Interleukin-18 promoter polymorphism is associated with lung cancer: a case-control study. Acta Oncol, 48, 971-6. https://doi.org/10.1080/02841860902878145
- Fujita K, Ewing CM, Isaacs WB, Pavlovich CP (2011). Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int J Cancer, 129, 424-32. https://doi.org/10.1002/ijc.25705
- Gollob JA, Mier JW, Veenstra K, et al (2000). Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res, 6, 1678-92.
- Haghshenas MR, Hosseini SV, Mahmoudi M, Saberi-Firozi M, Farjadian S, Ghaderi A (2009). IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J Gastroenterol Hepatol, 24, 1119-22. https://doi.org/10.1111/j.1440-1746.2009.05791.x
- Han Ming-yong, Zheng Shu, Yu Jin-ming, et al (2004). Study on interleukin-18 gene transfer into human breast cancer cells to prevent tumorigenicity. J Zhejiang Univ SCI, 5, 472-6. https://doi.org/10.1631/jzus.2004.0472
- Ingram JT, Yi JS, Zajac AJ (2011). Exhausted CD8 T cells downregulate the IL-18 receptor and become unresponsive to inflammatory cytokines and bacterial co-infections. PLoS Pathog, 7, 1002273. https://doi.org/10.1371/journal.ppat.1002273
- Jablonska E, Puzewska W, Grabowska Z, Jablonski J, Talarek L (2005). VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer. Cytokine, 30, 93-9. https://doi.org/10.1016/j.cyto.2004.12.004
- Jebreel A, Mistry D, Loke D, et al (2007). Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol, 121, 246-52.
- Jung MK, Park Y, Song SB, et al (2011). Erythroid differentiation regulator 1, an interleukin 18-regulated gene, acts as a metastasis suppressor in melanoma. J Invest Dermatol, 131, 2096-104. https://doi.org/10.1038/jid.2011.170
- Kang JS, Bae SY, Kim HR, et al (2009). Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44. Carcinogenesis, 30, 1987-96. https://doi.org/10.1093/carcin/bgp158
- Kaser A, Novick D, Rubinstein M, et al (2002). Tilg interferon-a induces interleukin-18 binding protein in chronic hepatitis C patients. Clin Exp Immunol, 129, 332-8 https://doi.org/10.1046/j.1365-2249.2002.01911.x
- Kei-ichi Y, Rachael C, Rebecca D, et al (2006). Kupper1 Expression of Interleukin-18 and Caspase-1in Cutaneous T-Cell Lymphoma. Clin Cancer Res, 12, 2.
- Khalili-Azad T, Razmkhah M, Ghiam AF, et al (2009). Association of interleukin-18 gene promoter polymorphisms with breast cancer. Neoplasma, 56, 22-5. https://doi.org/10.4149/neo_2009_01_22
- Khatri A, Husaini Y, Ow K, Chapman J, Russell PJ (2009). Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines. Clin Cancer Res, 15, 2323-34. https://doi.org/10.1158/1078-0432.CCR-08-2039
- Kim J, Kim C, Kim TS, et al (2006). IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway. Biochem Biophys Res Commun, 344, 1284-9. https://doi.org/10.1016/j.bbrc.2006.04.016
- Kim J, Shao Y, Kim SY, et al (2008). Hypoxia-induced IL-18 increases hypoxia-inducible factor-1alpha expression through a Rac1-dependent NF-kappaB pathway. Mol Biol Cell, 19, 433-44.
- Kim KE, Song H, Hahm C, et al (2009). Expression of ADAM33 is a novel regulatory mechanism in IL-18-secreted process in gastric cancer. J Immunol, 182, 3548-55. https://doi.org/10.4049/jimmunol.0801695
- Kim KE, Song H, Kim TS, et al (2007). IL-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene, 26, 1468-76. https://doi.org/10.1038/sj.onc.1209926
- Kim YS, Cheong JY, Cho SW, et al (2009). A functional SNP of the Interleukin-18 gene is associated with the presence of hepatocellular carcinoma in hepatitis B virus-infected patients. Dig Dis Sci, 54, 2722-8. https://doi.org/10.1007/s10620-009-0970-6
- Kinoshita M, Miyazaki H, Ono S, et al (2011). Enhancement of neutrophil function by interleukin-18 therapy protects burn-injured mice from methicillin-resistant Staphylococcus aureus. Infect Immun, 79, 2670-80. https://doi.org/10.1128/IAI.01298-10
- Kuryliszyn-Moskal A, Dubicki A, Zarzycki W, Zonnenberg A, Gorska M (2011). Microvascular abnormalities in capillaroscopy correlate with higher serum IL-18 and sEselectin levels in patients with type 1 diabetes complicated by microangiopathy. Folia Histochem Cytobiol, 49, 104-10. https://doi.org/10.5603/FHC.2011.0015
- Ledee N, Petitbarat M, Rahmati M, et al (2011). New preconception immune biomarkers for clinical practice: interleukin-18, interleukin-15 and TWEAK on the endometrial side, G-CSF on the follicular side. J Reprod Immunol, 88, 118-23. https://doi.org/10.1016/j.jri.2011.01.007
- Li W, Kubo S, Okuda A, et al (2010). Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2. J Immunother, 33, 287-96. https://doi.org/10.1097/CJI.0b013e3181c80ffa
- Lissoni P, Brivio F, Rovelli F, et al (2000). Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J Biol Regul Homeost Agents, 14, 275-7.
- Liu Y, Lin N, Huang L, Xu Q, Pang G (2007). Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol, 26, 613-8. https://doi.org/10.1089/dna.2007.0600
- Majima T, Ichikura T, Chochi K, et al (2006). Exploitation of interleukin-18 by gastric cancers for their growth and evasion of host immunity. Int J Cancer, 118, 388-95. https://doi.org/10.1002/ijc.21334
- Majima T, Ichikura T, Seki S, et al (2002). The influence of interleukin-10 and interleukin-18 on interferon-gamma production by peritoneal exudate cells in patients with gastric carcinoma. Anticancer Res, 22, 1193-9.
- Michael JR, John MK, Theodore FL, et al (2010). Dar4 A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer. Clin Cancer Res, 14, 11.
- Mohran ZY, Ali-Eldin FA, Abdel Aal HA (2011). Serum interleukin-18: does it have a role in the diagnosis of hepatitis C virus related hepatocellular carcinoma? Arab J Gastroenterol, 12, 29-33. https://doi.org/10.1016/j.ajg.2010.11.002
- Mojtahedi Z, Khademi B, Hashemi SB, et al (2011). Serum interleukine-6 concentration, but not interleukine-18, is associated with head and neck squamous cell carcinoma progression. Pathol Oncol Res, 17, 7-10. https://doi.org/10.1007/s12253-010-9261-y
- Muller J, Feige K, Wunderlin P, et al (2011). Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses. J Immunother, 34, 58-64. https://doi.org/10.1097/CJI.0b013e3181fe1997
- Nilkaeo A, Bhuvanath S (2006). Role of interleukin-18 in modulation of oral carcinoma cell proliferation. Mediators Inflamm, 3, 67120.
- Nishio S, Yamada N, Ohyama H, et al (2008). Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alphagalactosylceramide and interleukin-18. Cancer Sci, 99, 113-20.
- Nong LG, Luo B, Zhang L, Nong HB (2009). Interleukin-18 gene promoter polymorphism and the risk of nasopharyngeal carcinoma in a Chinese population. DNA Cell Biol, 28, 507-13. https://doi.org/10.1089/dna.2009.0912
- Okamoto M, Azuma K, Hoshino T, et al (2009). Correlation of decreased survival and IL-18 in bone metastasis. Intern Med, 48, 763-73. https://doi.org/10.2169/internalmedicine.48.1851
- Orengo AM, Fabbi M, Miglietta L, et al (2010). Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor. Int J Cancer.
- Page F, Galon J, Galina K, et al (2005). Wolf-Herman Fridman, and Berthold Henglein Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood, 105, 1632-9. https://doi.org/10.1182/blood-2004-08-3196
- Park CC, Morel JC, Amin MA, et al (2001). Evidence of IL-18 as a novel angiogenic mediator. J Immunol, 167, 1644-53. https://doi.org/10.4049/jimmunol.167.3.1644
- Park S, Cheon S, Cho D (2007). The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol, 4, 329-35.
- Qiao H, Sonoda KH, Ikeda Y, et al (2007). IL-18 regulates pathological intraocular neovascularization. J Leukoc Biol, 81, 1012-21. https://doi.org/10.1189/jlb.0506342
- Redlinger RE Jr, Mailliard RB, Lotze MT, Barksdale EM Jr (2003). Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo. J Pediatr Surg, 38, 301-7. https://doi.org/10.1053/jpsu.2003.50098
- Robertson MJ, Mier JW, Logan T, et al (2006). Clinical and biological effects of recombinant humaninterleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res, 12, 4265-73. https://doi.org/10.1158/1078-0432.CCR-06-0121
- Rovina N, Hillas G, Dima E, et al (2011). VEGF and IL-18 in induced sputum of lung cancer patients. Cytokine, 54, 277-81. https://doi.org/10.1016/j.cyto.2011.02.014
- Sabel MS, Su G, Griffith KA, Chang AE (2010). Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer. Breast Cancer Res Treat, 122, 325-36. https://doi.org/10.1007/s10549-009-0570-3
- Saenz-Lopez P, Carretero R, Vazquez F, et al (2010). Impact of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of renal cell carcinoma patients. Hum Immunol, 71, 309-13. https://doi.org/10.1016/j.humimm.2009.11.010
- Salado C, Olaso E, Gallot N, et al (2011). Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. J Transl, 9, 59. https://doi.org/10.1186/1479-5876-9-59
- Salcedo R, Worschech A, Cardone M, et al (2010).MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med, 207, 1625-36. https://doi.org/10.1084/jem.20100199
- Samsami DA, Shahriary K, Kashef MA, et al (2009). Interleukin-18 gene promoter and serum level in women with ovarian cancer. Mol Biol Rep, 36, 2393-7. https://doi.org/10.1007/s11033-009-9469-7
- Setsuda J, Teruya-Feldstein J, Harris NL, et al (1999). Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease. Am J Pathol, 155, 257-65. https://doi.org/10.1016/S0002-9440(10)65119-X
- Skopiński P, Rogala E, Duda-Krol B, et al (2005). Increased IL-18 content and angiogenic activity of sera from diabetic (Type 2) patients with background retinopathy. J Diabetes Complications, 19, 335-8. https://doi.org/10.1016/j.jdiacomp.2005.02.008
- Sobti RC, Shekari M, Tamandani DM, Malekzadeh K, Suri V (2008). Association of interleukin-18 gene promoter polymorphism on the risk of cervix carcinogenesis in north Indian population. Oncol Res, 17, 159-66. https://doi.org/10.3727/096504008785114156
- Song H, Kim J, Lee HK, et al (2011). Selenium inhibits migration of murine melanoma cells via down-modulation of IL-18 expression. Int Immunopharmacol.
- Srabovic N, Mujagic Z, Mujanovic-Mustedanagic J, Muminovic Z, Cickusic E (2011). Interleukin 18 expression in the primary breast cancer tumour tissue. Med Glas Ljek komore Zenicko-doboj kantona, 8, 109-15.
- Tangkijvanich P, Thong-Ngam D, Mahachai V, Theamboonlers A, Poovorawan Y (2007). Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol, 13, 4345-9. https://doi.org/10.3748/wjg.v13.i32.4345
- Tasaki K, Yoshida Y, Maeda T, et al (2000). Protective immunity is induced in murine colon carcinoma cells by the expression of IL-12 orIL-18, which activate type 1 helper T cells. Cancer Gene Ther, 7, 247-54. https://doi.org/10.1038/sj.cgt.7700094
- Terme M, Ullrich E, Aymeric L, et al (2011). IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res, 71, 5393-9. https://doi.org/10.1158/0008-5472.CAN-11-0993
- Thong-Ngam D, Tangkijvanich P, Lerknimitr R, et al (2006). Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol, 12, 4473-7. https://doi.org/10.3748/wjg.v12.i28.4473
- Tsuboi K, Miyazaki T, Nakajima M, et al (2004). Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma. Cancer Lett, 205, 207-14. https://doi.org/10.1016/j.canlet.2003.10.010
- Tsurumi H, Kasahara S, Kanemura N, et al (2011). Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. Eur J Haematol, 87, 217-27. https://doi.org/10.1111/j.1600-0609.2011.01649.x
- Vairaktaris E, Serefoglou ZC, Yapijakis C, et al (2007). The interleukin-18 -607A/C polymorphism is not associated with risk for oral cancer. Anticancer Res, 27, 4011-4.
- Volin MV, Koch AE (2011). IL-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis. J Interferon Cytokine Res, 31, 745-51. https://doi.org/10.1089/jir.2011.0050
- Wang Y, Chaudhri G, Jackson RJ, Karupiah G (2009). IL-12p40 and IL-18 play pivotal roles in orchestrating the cell-mediated immune response to a poxvirus infection. J Immunol, 183, 3324-31 https://doi.org/10.4049/jimmunol.0803985
- Wei YS, Lan Y, Liu YG, et al (2007). Interleukin-18 gene promoter polymorphisms and the risk of esophageal squamous cell carcinoma. Acta Oncol, 46, 1090-6. https://doi.org/10.1080/02841860701373595
- Yang Y, Qiao J, Li MZ (2010). Association of polymorphisms of interleukin-18 gene promoter region with polycystic ovary syndrome in chinese population. Reprod Biol Endocrinol, 8, 125. https://doi.org/10.1186/1477-7827-8-125
- Yao JC, Phan A, Hoff PM, et al (2008). Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol, 26, 1316-23. https://doi.org/10.1200/JCO.2007.13.6374
- Yao L, Setsuda J, Sgadari C, Cherney B, Tosato G (2001). Interleukin-18 expression induced by Epstein-Barr virusinfected cells. J Leukoc Biol, 69, 779-84.
- Yao L, Zhang Y, Chen K, Hu X, Xu LX (2011). Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox. PLoS One, 6, 24684. https://doi.org/10.1371/journal.pone.0024684
- Ye ZB, Ma T, Li H, Jin XL, Xu HM (2007). Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol, 13, 1747-51. https://doi.org/10.3748/wjg.v13.i11.1747
- Yeh WL, Lu DY, Liou HC, Fu WM (2011). A forward loop between glioma and microglia: glioma-derived extracellular matrix-activated microglia secrete IL-18 to enhance the migration of glioma cells. J Cell Physiol.
- Yoneda S, Umemura T, Katsuyama Y, et al (2011) Association of serum cytokine levels with treatment response to pegylated interferon and ribavirintherapy in genotype 1 chronic hepatitis C patients. J Infect Dis, 203, 1087-95. https://doi.org/10.1093/infdis/jiq165
- Young-Ik Son, Ramsey MD, Robbie BM, et al (2001). Lotze Interleukin-18 (IL-18) Synergizes with IL-2 to Enhance Cytotoxicity, Interferon-g Production, and Expansion of Natural Killer Cells1. Cancer Res, 61, 884-8.
- Zaki MH, Vogel P, Body-Malapel M, Lamkanfi M, Kanneganti TD (2010). IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol, 185, 4912-20. https://doi.org/10.4049/jimmunol.1002046
- Zhang Y, Li Y, Ma Y, et al (2011). Dual effects of interleukin-18: inhibiting hepatitis B virus replication in HepG2.2.15 cells and promoting hepatoma cells metastasis. Am J Physiol Gastrointest Liver Physiol, 301, 565-73. https://doi.org/10.1152/ajpgi.00058.2011
Cited by
- Interleukin-18 Synergism with Interleukin-2 in Cytotoxicity and NKG2D Expression of Human Natural Killer Cells vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7857
- Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+ NK Cells vol.4, pp.1, 2015, https://doi.org/10.1038/srep05177
- RETRACTED ARTICLE: Significance of Increased Serum Interleukin-18 Levels in Stroke Patients: A Meta-Analysis vol.52, pp.3, 2015, https://doi.org/10.1007/s12035-014-8977-1
- Mesenchymal stem cells expressing interleukin-18 suppress breast cancer cells in vitro vol.9, pp.4, 2015, https://doi.org/10.3892/etm.2015.2286